Breaking News

Merck KGaA Selects PRA’s Remote Patient Monitoring Platform

Adding layer of technology to HGH treatments aims to facilitate better patient compliance.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Merck KGaA, Darmstadt, Germany, known in the U.S. as EMD Serono, has selected PRA Health Sciences’ remote patient monitoring platform to work in combination with its human growth hormone (HGH) treatment system. Under this agreement, PRA’s remote patient monitoring platform backs Merck KGaA’s HGH treatment system, including growlinkTM, a mobile app for patients prescribed with HGH treatment, and easypod® Connect, a secure platform for healthcare professionals (HCP) in the field of endocrinology t...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters